What we want versus what we can get: A closer look at failure time endpoints for cardiovascular studies

Journal of Biopharmaceutical Statistics

Volumn 18, Issue 2, 2008, Pages 370-381

  Song, Rui ^a   Cook, Thomas D ^b   Kosorok, Michael R ^a  

^a University of North Carolina at Chapel Hill   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Cardiovascular clinical trials; Competing risks; Composite endpoint; Recurrent events

Indexed keywords

ATENOLOL; CARVEDILOL; LOSARTAN; PLACEBO;

CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CLINICAL DECISION MAKING; CLINICAL RESEARCH; CLINICAL TRIAL; FATALITY; HAZARD RATIO; HEART FAILURE; HOSPITALIZATION; HUMAN; HYPERTENSION; INTERMETHOD COMPARISON; OUTCOME ASSESSMENT; OUTCOMES RESEARCH; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVIEW; STATISTICAL ANALYSIS; STATISTICS; THERAPY EFFECT; VALIDATION STUDY; VALIDITY;

CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; DATA INTERPRETATION, STATISTICAL; ENDPOINT DETERMINATION; HUMANS; MODELS, STATISTICAL; TREATMENT OUTCOME;

EID: 40449116327     PISSN: 10543406     EISSN: 15205711     Source Type: Journal    
DOI: 10.1080/10543400701697224     Document Type: Review

References (20)

1. Bernardo, P. M. V., Harrington, D. P. (2001). Sample size calculations for the two-sample problem using the multiplicative intensity model. Statistics in Medicine 20:557-579.
2. Braunwald, E., Cannon, C. P., McCabe, C. H. (1993). Use of composite endpoint in thrombolysis trials of acute myocardial infarction. American Journal of Cardiology 72:3G-12G.
3. Califf, R. M., Woodlief, L. H. (1997). Pragmatic and mechanistic trials. European Heart Journal 18:367-370.
4. Cook, R. J. (1995). The design and analysis of randomized trials with recurrent events. Statistics in Medicine 14:2081-2098.
5. DeMets, D. L., Califf, R. M. (2002). Lessons learned from recent cardiovascular clinical trials. Circulation 106:746-751.
6. Devereux, R. B., Dahlof, B., Kjeldsen, S. E., Julius, S., Aurup, P. et al. (2003). Effects of losartan or atenolol in hypertensive patients without clinically evidence vascular disease: A substudy of the LIFE Pfisterer randomized trial. Ann. Intern. Med. 139:169-177.
7. Freemantle, N., Calvert, M., Wood, J., Eastaugh, J., Griffin, C. (2003). Composite outcomes in randomized trials greater precision but with greater uncertainty? Journal of the American Medical Association 289:2554-2559.
8. Friedman, L. M., Furberg, C. D., DeMets D. L. (1998). Fundamentals of Clinical Trials. New York: Springer.
9. Lawless, J. F., Nadeau, J. C. (1995). Nonparametric estimation of cumulative mean functions for recurrent events. Technometrics 37:158-168.
10. Lin, D. Y., Robins, J. M., Wei, L. J. (1996). Comparing two failure time distributions in the presence of dependent censoring. Biometrika 83:381-393.
11. Matsui, S. (2005). Sample size calculations for comparative clinical trials with over-dispersed Poisson process data. Statistics in Medicine 24:1339-1356.
12. Meinert, C. L. (1996). Clinical Trials Dictionary. Baltimore MD: The Johns Hopkins Center for Clinical Trials.
13. Montori, V. M., Permanyer-Miralda, G., Ferreira-Gonzlez, I., Busse, W. J., Pacheco-Huergo, V., Bryant, D., Alonso, J., Akl, A. E., Domingo-Salvany, A., Mills, E., Wu, P., Schnemann, J. H., Jaeschke, R., Guyatt, R. H. (2005). Validity of composite endpoint in clinical trials. British Medical Journal 330:594-596.
14. Neaton, J. D., Gray, G., Zuckerman, B. D., Konstam, M. A. (2005). Key issues in end point selection for heart failure trials: Composite endpoint. Journal of Cardiac Failure 11:567-575.
15. Packer, M., Coats, A. J., Fowler, M. B. et al. (2001). Effect of carvedilol on the survival of patients with severe chronic heart failure. New England Journal of Medicine 344(22):1651-1658.
16. Penston, J. (2005). Composite end-points in clinical trials. http://www.bmj.com/cgi/ eletters/330/7491/594.
17. Pfisterer, M., Buser, P., Osswald. S., et al. (2003). Outcome of elderly patients with chronic symptomatic coronary artery disease with an invasive vs optimized medical treatment strategy: one-year results of the randomized TIME trial. Journal of the American Medical Association 289:1117-1123.
18. Robins, J. M. (1995). An analytic method for randomized trials with informative censoring: Part I. Lifetime Data Analysis 1:241-254.
19. Tian, L., Zucker, D., Wei, L. (2005). On the Cox model with time-varying regression coefficients. Journal of the American Statistical Association 100(469):172-183.
20. Zhang, J. L., Rubin, D. B. (2003). Estimation of causal effects via principal stratification when some outcomes are truncated by "death." Journal of Educational and Behavioral Statistics 28:353-368.